Trial Profile
A Phase 2, Randomised, Double-Blind, Placebo-Controlled Study of IC14 for Treatment of Patients With Rapidly Progressive Motor Neuron Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Atibuclimab (Primary)
- Indications Amyotrophic lateral sclerosis; Motor neuron disease
- Focus Biomarker; Therapeutic Use
- Sponsors Implicit Bioscience
- 13 May 2020 Planned End Date changed from 15 Dec 2020 to 15 Dec 2021.
- 13 May 2020 Planned primary completion date changed from 15 May 2020 to 15 May 2021.
- 13 May 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.